FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations
about
Class III Receptor Tyrosine Kinases in Acute Leukemia - Biological Functions and Modern Laboratory AnalysisPost-remission therapy for acute myeloid leukemiaClinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.Niche-mediated depletion of the normal hematopoietic stem cell reservoir by Flt3-ITD-induced myeloproliferation.Molecular therapy for acute myeloid leukaemia.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaSmall-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapiesImproving outcomes for patients with acute myeloid leukemia in first relapse: a single center experiencePhase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.Computer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors.Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug.Degradation of HK2 by chaperone-mediated autophagy promotes metabolic catastrophe and cell deathMicroenvironmental hypoxia regulates FLT3 expression and biology in AML.All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia.The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.Minimal residual disease in acute myeloid leukemia--current status and future perspectives.RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.Inhibition of FLT3 in AML: a focus on sorafenib.High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in FLT3 internal tandem duplication (ITD) negative patients in adult acute myeloid leukaemia: A prospective pilot study from India.Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cellsDual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growthDefining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia.Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles.Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.Sunitinib effectively reduces clonogenic acute myeloid leukemia cells in vitro.Advances in targeted therapy for acute myeloid leukaemia.Concomitant monitoring of WT1 and FLT3-ITD expression in FLT3-ITD acute myeloid leukemia patients: which should we trust as a minimal residual disease marker?Selective inhibition of the myeloid Src-family kinase Fgr potently suppresses AML cell growth in vitro and in vivo.
P2860
Q26797245-50D532C1-F09C-4577-9E97-DA3F691B87ACQ26995867-4BD68B3A-0FE2-4E12-B861-D589A29D169DQ33572303-FB530064-D8B2-4709-917E-F593628D356FQ33886530-41033F18-25B8-49EF-8C8C-94AAA7F14394Q33925672-5D377C53-6A4C-4541-A88E-3D4CE9C13B5BQ33943277-CAAEA47C-5D8A-4F67-823C-7DA7418D5556Q34158454-9A288285-89E7-4ABE-A865-F9AE9FEB0FE9Q34772229-E0F14638-6D30-48F1-806B-E24CCB5A647AQ35224437-1E2E215A-4BE3-4918-969E-714E57746497Q35560182-F4DDBEE2-AA17-40A2-976B-B2C01FA7D675Q35796826-50FFDAED-1E46-4E74-89AE-2D12124E564CQ36014637-31C274A2-0A98-4441-9039-700C6687FAD1Q36329436-B7957426-422D-4696-882F-CA042BCCF7A4Q36989582-C5F70ACB-B8B2-4C23-B519-591CA662DA6FQ37037268-4B16916D-2FB9-4517-BAA8-CF68E49628E6Q37699211-2467CC92-9E36-4BE5-86D9-15CEC6B9EC4BQ38216649-CB3CC98A-7482-44E6-A1C2-0D8B02511B5BQ38285175-E4D467C6-8CBE-481E-B440-B011F838E6C9Q38381981-6E9A7FE9-1B57-43E5-A02A-4F4A744A327DQ38494659-B61E2F72-3292-4FA2-8FEC-928DF34420DAQ38720331-B29F1F2A-87CA-40D4-9472-D1A8A8A8A4AEQ38857067-9B344240-D28C-4126-8037-A9596104C3ACQ38989349-7A094725-FFEC-402B-BB48-6443AD2F4B17Q39283692-330B3970-EBDC-4528-A232-7466DACE3851Q40985734-17164D5F-B9E0-4887-9A9B-68070AEB987DQ41071486-EF383143-4147-4FBF-B5B4-16F04F4EF72BQ41708770-0FB41794-7F12-42FC-A603-74A449F99A3EQ41818692-D4C17144-A69E-4655-86FA-0E30D0F8B956Q42385341-27BBCE05-3FB8-420E-9F62-BD84ECB45296Q42979880-332E81F4-F590-4EE3-88CD-B9BF2C393972Q46065833-CDB82565-9895-4EFA-8351-FB00A81FD4BAQ48204144-33625E3F-B362-4412-940E-5679B64F22AEQ48224336-FAE9756D-FFD9-4C81-9D9C-5B120FC4E743Q54109758-94A4C527-CF49-4D25-BBA0-B117419E2319
P2860
FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
FLT3 tyrosine kinase inhibitor ...... l implications and limitations
@ast
FLT3 tyrosine kinase inhibitor ...... l implications and limitations
@en
FLT3 tyrosine kinase inhibitor ...... l implications and limitations
@nl
type
label
FLT3 tyrosine kinase inhibitor ...... l implications and limitations
@ast
FLT3 tyrosine kinase inhibitor ...... l implications and limitations
@en
FLT3 tyrosine kinase inhibitor ...... l implications and limitations
@nl
prefLabel
FLT3 tyrosine kinase inhibitor ...... l implications and limitations
@ast
FLT3 tyrosine kinase inhibitor ...... l implications and limitations
@en
FLT3 tyrosine kinase inhibitor ...... l implications and limitations
@nl
P2860
P3181
P1433
P1476
FLT3 tyrosine kinase inhibitor ...... l implications and limitations
@en
P2093
Mark J Levis
Sabine Kayser
P2860
P304
P3181
P356
10.3109/10428194.2013.800198
P407
P577
2014-02-01T00:00:00Z